Genome engineering in the yeast pathogen Candida glabrata using the CRISPR-Cas9 system

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Enkler, Ludovic ^a   Richer, Delphine ^a   Marchand, Anthony L ^a   Ferrandon, Dominique ^a   Jossinet, Fabrice ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC PROTEINASE; DIFFERENTIATION ANTIGEN; DROSOPHILA PROTEIN; FUNGAL PROTEIN; IMMUNOGLOBULIN RECEPTOR; MYD88 PROTEIN, DROSOPHILA; PROTEIN SERINE THREONINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANIMAL; CANDIDA GLABRATA; CRISPR CAS SYSTEM; DROSOPHILA MELANOGASTER; FEMALE; FUNGAL GENOME; GENETIC ENGINEERING; GENETICS; HOMOLOGOUS RECOMBINATION; INDEL MUTATION; MICROBIOLOGY; PATHOGENICITY; PROCEDURES; VIRULENCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, DIFFERENTIATION; ASPARTIC ACID PROTEASES; CANDIDA GLABRATA; CRISPR-CAS SYSTEMS; DROSOPHILA MELANOGASTER; DROSOPHILA PROTEINS; FEMALE; FUNGAL PROTEINS; GENETIC ENGINEERING; GENOME, FUNGAL; HOMOLOGOUS RECOMBINATION; INDEL MUTATION; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, IMMUNOLOGIC; VIRULENCE;

EID: 84992363288     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep35766     Document Type: Article

References (62)

1. Almirante, B. et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from populationbased surveillance, barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 43, 1829-1835 (2005).
2. Lin, M. Y. et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a casecase-control study. Antimicrob. Agents Chemother. 49, 4555-4560 (2005).
3. Sandven, P. et al. Candidemia in Norway (1991 to 2003): results from a nationwide study. J. Clin. Microbiol. 44, 1977-1981 (2006).
4. Brown, G. D. et al. Hidden killers: human fungal infections. Sci Transl Med 4, 1-9 (2012).
5. Denning, D. W. & Bromley, M. J. Infectious Disease. How to bolster the antifungal pipeline. Science 347, 1414-1416 (2015).
6. Krcmery, V. & Barnes, A. J. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J. Hosp. Infect. 50, 243-260 (2002).
7. Vale-Silva, L. A. & Sanglard, D. Tipping the balance both ways: drug resistance and virulence in Candida glabrata. 15, 1-8 (2015).
8. Dujon, B. et al. Genome evolution in yeasts. Nature 430, 35-44 (2004).
9. Roetzer, A., Gabaldón, T. & Schüller, C. From Saccharomyces cerevisiae to Candida glabrata in a few easy steps: important adaptations for an opportunistic pathogen. FEMS Microbiology Letters 314, 1-9 (2010).
10. Gabaldón, T. & Carreté, L. The birth of a deadly yeast: tracing the evolutionary emergence of virulence traits in Candida glabrata. FEMS Yeast Res. 16, fov110 (2016).
11. de Groot, P. W. J. et al. The cell wall of the human pathogen Candida glabrata: differential incorporation of novel adhesin-like wall proteins. Eukaryotic Cell 7, 1951-1964 (2008).
12. Kaur, R., Ma, B. & Cormack, B. P. A family of glycosylphosphatidylinositol-linked aspartyl proteases is required for virulence of Candida glabrata. Proc. Natl. Acad. Sci. USA. 104, 7628-7633 (2007).
13. Bairwa, G., Rasheed, M., Taigwal, R., Sahoo, R. & Kaur, R. GPI (glycosylphosphatidylinositol)-linked aspartyl proteases regulate vacuole homoeostasis in Candida glabrata. Biochem. J. 458, 323-334 (2014).
14. Kasper, L., Seider, K. & Hube, B. Intracellular survival of Candida glabrata in macrophages: immune evasion and persistence. FEMS Yeast Res. 15, fov042 (2015).
15. Kaur, R., Domergue, R., Zupancic, M. L. & Cormack, B. P. A yeast by any other name: Candida glabrata and its interaction with the host. Curr. Opin. Microbiol. 8, 378-384 (2005).
16. Gabaldón, T. et al. Comparative genomics of emerging pathogens in the Candida glabrata clade. BMC Genomics 14, 623-638 (2013).
17. Ho, H.-L. & Haynes, K. Candida glabrata: new tools and technologies-expanding the toolkit. FEMS Yeast Res. 15, fov066 (2015).
18. Schwarzmüller, T. et al. Systematic phenotyping of a large-scale Candida glabrata deletion collection reveals novel antifungal tolerance genes. PLoS Pathog. 10, e1004211 (2014).
19. Castano, I. et al. Tn7-based genome-wide random insertional mutagenesis of Candida glabrata. Genome Res. 13, 905-915 (2003).
20. Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262-1278 (2014).
21. Qi, L. S. et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173-1183 (2013).
22. Anton, T., Bultmann, S., Leonhardt, H. & Markaki, Y. Visualization of specific DNA sequences in living mouse embryonic stem cells with a programmable fluorescent CRISPR/Cas system. Nucleus 5, 163-172 (2014).
23. Deng, W., Shi, X., Tjian, R., Lionnet, T. & Singer, R. H. CASFISH: CRISPR/Cas9-mediated in situ labeling of genomic loci in fixed cells. Proc. Natl. Acad. Sci. USA. 112, 11870-11875 (2015).
24. Jiang, W., Bikard, D., Cox, D., Zhang, F. & Marraffini, L. A. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat. Biotechnol. 31, 233-239 (2013).
25. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).
26. Nelson, C. E. et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351, 403-407 (2015).
27. Vinayak, S. et al. Genetic modification of the diarrhoeal pathogen Cryptosporidium parvum. Nature 523, 477-480 (2015).
28. Fuller, K. K., Chen, S., Loros, J. J. & Dunlap, J. C. Development of the CRISPR/Cas9 System for Targeted Gene Disruption in Aspergillus fumigatus. Eukaryotic Cell 14, 1073-1080 (2015).
29. Schuster, M., Schweizer, G., Reissmann, S. & Kahmann, R. Genome editing in Ustilago maydis using the CRISPR-Cas system. Fungal Genetics and Biology 89, 3-9 (2015).
30. Vyas, V. K., Barrasa, M. I. & Fink, G. R. A Candida albicans CRISPR system permits genetic engineering of essential genes and gene families. Science Advances 1, e1500248 (2015).
31. Quintin, J., Asmar, J., Matskevich, A. A., Lafarge, M.-C. & Ferrandon, D. The Drosophila Toll pathway controls but does not clear Candida glabrata infections. J. Immunol. 190, 2818-2827 (2013).
32. Brunke, S. et al. Of mice, flies-and men? Comparing fungal infection models for large-scale screening efforts. Dis Model Mech 8, 473-486 (2015).
33. Wightman, R., Bates, S., Amornrrattanapan, P. & Sudbery, P. In Candida albicans, the Nim1 kinases Gin4 and Hsl1 negatively regulate pseudohypha formation and Gin4 also controls septin organization. J. Cell Biol. 164, 581-591 (2004).
34. Jacobsen, I. D. et al. Candida glabrata persistence in mice does not depend on host immunosuppression and is unaffected by fungal amino acid auxotrophy. Infection and Immunity 78, 1066-1077 (2010).
35. Mota, S. et al. Candida glabrata susceptibility to antifungals and phagocytosis is modulated by acetate. Front Microbiol 6, 919 (2015).
36. Macreadie, I., Castelli, L., Mehra, R. & Winge, J. T. A. Heterologous gene expression and protein secretion from Candida glabrata. Biotechnology and Applied Biochemistry 19, 265-269 (1994).
37. Zordan, R. E. et al. Expression plasmids for use in Candida glabrata. G3 (Bethesda) 3, 1675-1686 (2013).
38. Marck, C. et al. The RNA polymerase III-dependent family of genes in hemiascomycetes: comparative RNomics, decoding strategies, transcription and evolutionary implications. Nucl. Acids Res. 34, 1816-1835 (2006).
39. DiCarlo, J. E. et al. Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucl. Acids Res. 41, 4336-4343 (2013).
40. Mumberg, D., Müller, R. & Funk, M. Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. Gene 156, 119-122 (1995).
41. Tauszig-Delamasure, S., Bilak, H., Capovilla, M., Hoffmann, J. A. & Imler, J.-L. Drosophila MyD88 is required for the response to fungal and Gram-positive bacterial infections. Nature Immunology 3, 91-97 (2001).
42. Clemmons, A. W., Lindsay, S. A. & Wasserman, S. A. An effector Peptide family required for Drosophila toll-mediated immunity. PLoS Pathog. 11, e1004876 (2015).
43. Reinders, J., Zahedi, R. P., Pfanner, N., Meisinger, C. & Sickmann, A. Toward the complete yeast mitochondrial proteome: multidimensional separation techniques for mitochondrial proteomics. J. Proteome Res. 5, 1543-1554 (2006).
44. Umeyama, T. et al. Candida albicans protein kinase CaHsl1p regulates cell elongation and virulence. Mol. Microbiol. 55, 381-395 (2005).
45. Binkley, J. et al. The Candida Genome Database: the new homology information page highlights protein similarity and phylogeny. Nucl. Acids Res. 42, D711-D716 (2014).
46. Martín, H., Rodríguez-Pachón, J. M., Ruiz, C., Nombela, C. & Molina, M. Regulatory mechanisms for modulation of signaling through the cell integrity Slt2-mediated pathway in Saccharomyces cerevisiae. J. Biol. Chem. 275, 1511-1519 (2000).
47. Krysan, D. J., Ting, E. L., Abeijon, C., Kroos, L. & Fuller, Rs. S. Yapsins are a family of aspartyl proteases required for cell wall integrity in Saccharomyces cerevisiae. Eukaryotic Cell 4, 1364-1374 (2005).
48. Levin, D. E. Regulation of cell wall biogenesis in Saccharomyces cerevisiae: the cell wall integrity signaling pathway. Genetics 189, 1145-1175 (2011).
49. Zhang, C., Meng, X., Wei, X. & Lu, L. Highly efficient CRISPR mutagenesis by microhomology-mediated end joining in Aspergillus fumigatus. Fungal Genet. Biol. 86, 47-57 (2015).
50. Kasper, L. et al. Identification of Candida glabrata genes involved in pH modulation and modification of the phagosomal environment in macrophages. PLoS ONE 9, e96015 (2014).
51. Bairwa, G. & Kaur, R. A novel role for a glycosylphosphatidylinositol-anchored aspartyl protease, CgYps1, in the regulation of pH homeostasis in Candida glabrata. Mol. Microbiol. 79, 900-913 (2011).
52. Brieland, J. et al. Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice. Infection and Immunity 69, 5046-5055 (2001).
53. Rai, M. N., Balusu, S., Gorityala, N., Dandu, L. & Kaur, R. Functional Genomic Analysis of Candida glabrata-Macrophage Interaction: Role of Chromatin Remodeling in Virulence. PLoS Pathog. 8, e1002863 (2012).
54. Fukuda, Y., Tsai, H.-F., Myers, T. G. & Bennett, J. E. Transcriptional profiling of Candida glabrata during phagocytosis by neutrophils and in the infected mouse spleen. Infection and Immunity 81, 1325-1333 (2013).
55. Limmer, S. et al. Pseudomonas aeruginosa RhlR is required to neutralize the cellular immune response in a Drosophila melanogaster oral infection model. Proc. Natl. Acad. Sci. USA. 108, 17378-17383 (2011).
56. Dardalhon, M. L., Lin, W., Nicolas, A. & Averbeck, D. Specific transcriptional responses induced by 8-methoxypsoralen and UVA in yeast. 7, 866-878 (2007).
57. Gagnon-Arsenault, I., Tremblay, J. & Bourbonnais, Y. Fungal yapsins and cell wall: a unique family of aspartic peptidases for a distinctive cellular function. FEMS Yeast Res. 6, 966-978 (2006).
58. Varshney, N. et al. A surprising role for the Sch9 protein kinase in chromosome segregation in Candida albicans. Genetics 199, 671-674 (2015).
59. Linde, J. et al. Defining the transcriptomic landscape of Candida glabrata by RNA-Seq. Nucl. Acids Res. 43, 1392-1406 (2015).
60. Xie, S., Shen, B., Zhang, C., Huang, X. & Zhang, Y. sgRNAcas9: a software package for designing CRISPR sgRNA and evaluating potential off-target cleavage sites. PLoS ONE 9, e100448 (2014).
61. Jiang, H. & Wong, W. H. SeqMap: mapping massive amount of oligonucleotides to the genome. Bioinformatics 24, 2395-2396 (2008).
62. Doench, J. G. et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat. Biotechnol. 32, 1262-1267 (2014).